330 related articles for article (PubMed ID: 22043109)
1. Manganese-based MRI contrast agents: past, present and future.
Pan D; Schmieder AH; Wickline SA; Lanza GM
Tetrahedron; 2011 Nov; 67(44):8431-8444. PubMed ID: 22043109
[TBL] [Abstract][Full Text] [Related]
2. Revisiting an old friend: manganese-based MRI contrast agents.
Pan D; Caruthers SD; Senpan A; Schmieder AH; Wickline SA; Lanza GM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(2):162-73. PubMed ID: 20860051
[TBL] [Abstract][Full Text] [Related]
3. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG
Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of a gadolinium based-macrocyclic MRI contrast agent for effective cancer diagnosis.
Jeong Y; Na K
Biomater Res; 2018; 22():17. PubMed ID: 29942642
[TBL] [Abstract][Full Text] [Related]
5. Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging.
Zhen Z; Xie J
Theranostics; 2012; 2(1):45-54. PubMed ID: 22272218
[TBL] [Abstract][Full Text] [Related]
6. The need for prophylactic hemodialysis to protect against nephrogenic systemic fibrosis in patients with end-stage renal disease receiving gadolinium-based contrast agents.
Lee Y; Kim J; Kwon S; Jeong JC; Joo KW; Oh KH
Acta Radiol; 2023 Aug; 64(8):2492-2496. PubMed ID: 37128169
[TBL] [Abstract][Full Text] [Related]
7. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.
Ersoy H; Rybicki FJ
J Magn Reson Imaging; 2007 Nov; 26(5):1190-7. PubMed ID: 17969161
[TBL] [Abstract][Full Text] [Related]
8. Mesoporous manganese silicate coated silica nanoparticles as multi-stimuli-responsive T1-MRI contrast agents and drug delivery carriers.
Li X; Zhao W; Liu X; Chen K; Zhu S; Shi P; Chen Y; Shi J
Acta Biomater; 2016 Jan; 30():378-387. PubMed ID: 26602820
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
